Overview Dividends

(REGN) Regeneron Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75886F1075

Eylea, Dupixent, Libtayo, Praluent, Kevzara

Biotechnology
Market Cap in USD: 78,113m

IPO / Inception: 1991-04-02
Return 12m vs S&P 500: -7.62%

EPS (Earnings per Share)

EPS CAGR: -14.54%
EPS Trend: -15.8%

Last SUE: 1.43
Qual. Beats: 2

Revenue

Rev. CAGR: -7.12%
Rev. Trend: 14.2%

Last SUE: 0.91
Qual. Beats: 2

Dividends

Dividend Yield	0.45%
Yield on Cost 5y	0.69%
Yield CAGR 5y	0.00%
Payout Consistency	100.0%
Payout Ratio	7.8%

Risk via 10d forecast
Volatility	39.4%
Value at Risk 5%th	60.3%
Relative Tail Risk	-6.86%

Reward TTM
Sharpe Ratio	0.28
Alpha	-4.11
CAGR/Max DD	0.03

Character TTM
Hurst Exponent	0.267
Beta	0.574
Beta Downside	0.433

Drawdowns 3y
Max DD	59.69%
Mean DD	19.87%
Median DD	7.03%

Description: REGN Regeneron Pharmaceuticals September 26, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a U.S.-based biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines across multiple therapeutic areas, including ophthalmology, immunology, oncology, cardiovascular, metabolic, infectious, and rare diseases.

Its flagship products generate the bulk of revenue: EYLEA (wet age-related macular degeneration and diabetic eye disease) delivered $2.0 billion in 2023 sales; Dupixent (atopic dermatitis and asthma) posted $2.5 billion; and Libtayo (cutaneous squamous-cell carcinoma) contributed $2.1 billion. Additional marketed therapies include Praluent, REGEN-COV, Kevzara, Inmazeb, ARCALYST, ZALTRAP, Evkeeza, Ordspono, and Veopoz, with a pipeline targeting eye, inflammatory, cardiovascular, metabolic, infectious, oncology, pain, and hematologic indications.

The company maintains a strong balance sheet, reporting approximately $5.5 billion of cash and marketable securities at year-end 2023, and it reinvested roughly $2.3 billion in R&D, reflecting its commitment to pipeline expansion. Key sector drivers-an aging global population increasing demand for ophthalmic and cardiovascular therapies, and sustained biotech R&D tax incentives in the United States-support Regeneron’s growth outlook.

Strategic collaborations extend Regeneron’s capabilities: a partnership with Mammoth Biosciences to develop in-vivo CRISPR-based gene-editing therapies, and an alliance with Sonoma Biotherapeutics to advance engineered regulatory T-cell treatments, both aimed at diversifying its product portfolio beyond conventional biologics.

For a deeper, data-driven valuation framework, you might explore the detailed analyst models available on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (4.58b TTM) > 0 and > 6% of Revenue (6% = 854.9m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA 1.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 95.14% (prev 113.2%; Δ -18.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 5.07b > Net Income 4.58b (YES >=105%, WARN >=100%)

Net Debt (199.1m) to EBITDA (5.71b) ratio: 0.03 <= 3.0 (WARN <= 3.5)

Current Ratio 4.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (107.2m) change vs 12m ago -7.75% (target <= -2.0% for YES)

Gross Margin 85.39% (prev 85.31%; Δ 0.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 36.72% (prev 36.98%; Δ -0.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 123.2 (EBITDA TTM 5.71b / Interest Expense TTM 42.1m) >= 6 (WARN >= 3)

Altman Z'' 9.96

(A) 0.34 = (Total Current Assets 17.98b - Total Current Liabilities 4.43b) / Total Assets 40.17b

(B) 0.87 = Retained Earnings (Balance) 35.05b / Total Assets 40.17b

warn (B) unusual magnitude: 0.87 — check mapping/units

(D) 3.81 = Book Value of Equity 35.11b / Total Liabilities 9.21b

Total Rating: 9.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 75.69

1. Piotroski 7.0pt

2. FCF Yield 5.74%

3. FCF Margin 29.16%

4. Debt/Equity 0.09

5. Debt/Ebitda 0.03

6. ROIC - WACC (= 5.59)%

7. RoE 15.31%

8. Rev. Trend 14.15%

9. EPS Trend -15.80%

What is the price of REGN shares?

As of November 26, 2025, the stock is trading at USD 787.32 with a total of 1,200,455 shares traded.
Over the past week, the price has changed by +8.68%, over one month by +34.68%, over three months by +37.72% and over the past year by +5.63%.

Is REGN a buy, sell or hold?

Regeneron Pharmaceuticals has received a consensus analysts rating of 4.28. Therefore, it is recommended to buy REGN.

Strong Buy: 14
Buy: 5
Hold: 5
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the REGN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	755.4	-4%
Analysts Target Price	755.4	-4%
ValueRay Target Price	791	0.5%

REGN Fundamental Data Overview November 22, 2025

Market Cap USD = 78.11b (78.11b USD * 1.0 USD.USD)
P/E Trailing = 17.6696
P/E Forward = 16.6945
P/S = 5.4824
P/B = 2.3858
P/EG = 1.3965
Beta = 0.386
Revenue TTM = 14.25b USD
EBIT TTM = 5.19b USD
EBITDA TTM = 5.71b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 199.1m USD (from netDebt column, last quarter)
Enterprise Value = 72.37b USD (78.11b + Debt 2.71b - CCE 8.44b)
Interest Coverage Ratio = 123.2 (Ebit TTM 5.19b / Interest Expense TTM 42.1m)
FCF Yield = 5.74% (FCF TTM 4.15b / Enterprise Value 72.37b)
FCF Margin = 29.16% (FCF TTM 4.15b / Revenue TTM 14.25b)
Net Margin = 32.13% (Net Income TTM 4.58b / Revenue TTM 14.25b)
Gross Margin = 85.39% ((Revenue TTM 14.25b - Cost of Revenue TTM 2.08b) / Revenue TTM)
Gross Margin QoQ = 86.11% (prev 85.58%)
Tobins Q-Ratio = 1.80 (Enterprise Value 72.37b / Total Assets 40.17b)
Interest Expense / Debt = 0.71% (Interest Expense 19.3m / Debt 2.71b)
Taxrate = 17.20% (303.3m / 1.76b)
NOPAT = 4.29b (EBIT 5.19b * (1 - 17.20%))
Current Ratio = 4.06 (Total Current Assets 17.98b / Total Current Liabilities 4.43b)
Debt / Equity = 0.09 (Debt 2.71b / totalStockholderEquity, last quarter 30.96b)
Debt / EBITDA = 0.03 (Net Debt 199.1m / EBITDA 5.71b)
Debt / FCF = 0.05 (Net Debt 199.1m / FCF TTM 4.15b)
Total Stockholder Equity = 29.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.40% (Net Income 4.58b / Total Assets 40.17b)
RoE = 15.31% (Net Income TTM 4.58b / Total Stockholder Equity 29.91b)
RoCE = 16.26% (EBIT 5.19b / Capital Employed (Equity 29.91b + L.T.Debt 1.99b))
RoIC = 13.47% (NOPAT 4.29b / Invested Capital 31.89b)
WACC = 7.88% (E(78.11b)/V(80.82b) * Re(8.13%) + D(2.71b)/V(80.82b) * Rd(0.71%) * (1-Tc(0.17)))
Discount Rate = 8.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -2.94%
[DCF Debug] Terminal Value 75.34% ; FCFE base≈3.84b ; Y1≈3.26b ; Y5≈2.50b
Fair Price DCF = 436.1 (DCF Value 45.04b / Shares Outstanding 103.3m; 5y FCF grow -18.28% → 3.0% )
EPS Correlation: -15.80 | EPS CAGR: -14.54% | SUE: 1.43 | # QB: 2
Revenue Correlation: 14.15 | Revenue CAGR: -7.12% | SUE: 0.91 | # QB: 2

Additional Sources for REGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle